Kilitch Drugs (India)
KILITCHNSE

Kilitch Drugs (India)

₹138.650.30 (0.22%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
132.20
Today’s high
139.94
52 week low
117.25
52 week high
250.00
Open price
138.00
Previous close
138.35
Live volume
10,083
Lower circuit
110.92
Upper circuit
166.38

Fundamentals

Market Cap
₹486Cr
ROE
10.38%
P/E Ratio(TTM)
19.57
EPS(TTM)
7.10
P/B Ratio
1.83
Dividend Yield
0.00%
Industry P/E
31.31
Book Value
75.99
Debt to Equity
0.31
Face Value
10

Financials

*All values are in Rs. Cr
No Graph Data To Display
Quarterly
Yearly

About

Kilitch Drugs (India) Limited is one of the world's leading and fastest-growing pharmaceutical companies, manufacturing and supplying a broad range of formulations globally. The company embraces purpose-driven leadership to create long-term value beyond financial performance, establishing itself as a significant entity in the pharmaceutical industry. It is committed to achieving sustainable healthcare by optimizing its processes and practices through continuous innovation and sustainable operations. Its extensive research has developed a diverse portfolio targeting chronic and acute treatments, including injectables, ophthalmics, effervescent tablets, and nutraceuticals. With a formidable presence across Asia, Africa, CIS, and Latin America, the company offers a broad product portfolio to suit each country's needs. A key international asset is its Ethiopia Unit, the largest Cephalosporin plant in East Africa, producing tablets, capsules, and injectables.;
MD/CEO
Mukund Mehta
Founded in
1992
NSE symbol
KILITCH
Industry

Shareholding Pattern

Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Promoters
63.77%
Retail And Others
36.22%

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
Innova CaptabINNOVACAP
₹704.40
+0.45 (0.06%)
L
    H
    4,025.7730.43.94
    ₹388.25
    -4.50 (1.15%)
    L
      H
      3,640.7240.624.99
      Aarti DrugsAARTIDRUGS
      ₹352.70
      +6.30 (1.82%)
      L
        H
        3,213.1615.872.19
        ₹288.60
        -0.10 (0.03%)
        L
          H
          2,905.6958.074.6
          Livesquawk
          Kilitch Drugs approves 1:1 bonus issue, doubling shareholder holdings.
          Livesquawk
          Kilitch Drugs' Q3 net profit fell to ₹44M from ₹60M YoY. Revenue declined to ₹538M in Q3, compared to ₹562M YoY.
          Livesquawk
          Kilitch Drugs reported Q2 net profit of ₹81.8M, down from ₹86.2M YoY. Q2 revenue rose to ₹489.2M, EBITDA to ₹40.7M, margin improved to 17.1% from 15.1% YoY.
          2026

          24
          Mar
          Bonus
          Ex date
          1:1
          Ratio

          For every 1 shares you hold, you will receive 1 additional shares
          Bonus ratio1:1
          Ex date24 Mar ‘26
          Record date24 Mar ‘26
          Announcement date18 Mar ‘26

          18
          Mar
          Bonus
          Announced
          1:1
          Ratio

          For every 1 shares you hold, you will receive 1 additional shares
          Bonus ratio1:1
          Ex date24 Mar ‘26
          Record date24 Mar ‘26
          Announcement date18 Mar ‘26
          11
          Feb
          Quarterly Result
          Release date
          2025
          13
          Nov
          Quarterly Result
          Release date
          13
          Aug
          Quarterly Result
          Release date

          15
          Jul
          Rights Entitlement
          Ex date
          2:23
          Ratio

          2 rights eligible for every 23 existing shares held
          Ratio2:23
          Offer price₹357.00
          Ex date15 Jul ‘25
          Record date15 Jul ‘25
          Announcement date9 Jul ‘25

          9
          Jul
          Rights Entitlement
          Announced
          2:23
          Ratio

          2 rights eligible for every 23 existing shares held
          Ratio2:23
          Offer price₹357.00
          Ex date15 Jul ‘25
          Record date15 Jul ‘25
          Announcement date9 Jul ‘25
          Events calendar
          View upcoming events in other stocks